1-[(2-Bromophenyl)sulfanyl]-2,4-dimethylbenzene

We are 1-[(2-Bromophenyl)sulfanyl]-2,4-dimethylbenzene CAS:960203-41-2 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:  1-[(2-Bromophenyl)sulfanyl]-2,4-dimethylbenzene
CAS.NO: 960203-41-2
Synonyms:
1-[(2-Bromophenyl)sulfanyl]-2,4-dimethylbenzene
1-[(2-Bromophenyl)thio]-2,4-dimethylbenzene
Benzene, 1-[(2-bromophenyl)thio]-2,4-dimethyl-
(2-bromophenyl)(2,4-dimethylphenyl)sulfane

Molecular Formula: C14H13BrS
Molecular Weight: 293.222

Physical and Chemical Properties:
Density: 1.4±0.1 g/cm3
Boiling point:329.2±30.0 °C at 760 mmHg
Melting point:/
Flash point:152.9±24.6 °C
Refractive index:1.651

Specification:
Appearance: /
Purity:≥97%

Packing:
 25kg  cardboard drum or according to customer specified requirements
Storage:Refrigerator (+4ºC)。Stored in a cool and dry well-closed container. Keep away from moisture and strong light/heat.
Application:Intermediates of Vortioxetine hydrobromide CAS:960203-27-4

1-[(2-Bromophenyl)sulfanyl]-2,4-dimethylbenzene


Related News: The first is the API – which is the central ingredient.7-Fluoro-6-nitro-4-hydroxyquinazoline The first is the API – which is the central ingredient.4,7-Dichloroquinoline The outlook for a cure is clouded with theoretical uncertainties and high-profile failures. Pharmaceutical giants including Johnson & Johnson, Merck and Pfizer have ditched their projects on unsatisfactory data.2-Bromo-1-[4-hydroxy-3-(hydroxymethyl)phenyl]ethanone CAS:62932-94-9 INSPIRE is a global, multi-center, randomized, controlled study to assess the efficacy and safety of IV rigosertib in higher-risk MDS (HR-MDS) patients who had progressed on, failed to respond to, or relapsed after previous treatment with a hypomethylating agent (HMA) within nine cycles over the course of one year after initiation of HMA treatment.INSPIRE is a global, multi-center, randomized, controlled study to assess the efficacy and safety of IV rigosertib in higher-risk MDS (HR-MDS) patients who had progressed on, failed to respond to, or relapsed after previous treatment with a hypomethylating agent (HMA) within nine cycles over the course of one year after initiation of HMA treatment.

Related Products
Product Name
9-(3-bromophenyl)-10-phenylanthracene View Details
4-Methylbenzotrifluoride View Details
4-chloro-1-benzothiophene View Details
4-fluoro-3-nitroaniline manufacturer 1-dimethoxyphosphoryl-3-phenoxypropan-2-one manufacturer 2-Amino-5-chlorobenzotrifluoride manufacturer 1-Bromo-4-(trifluoromethoxy)benzene manufacturer 1-Bromo-8-fluorooctane manufacturer